Is IMTX or IRD more profitable?

Immatics has a net margin of -572.35% compared to Opus Genetics' net margin of -892.36%. Immatics' return on equity of -47.36% beat Opus Genetics' return on equity. Company Net Margins Return on Equity Return on Assets Immatics -572.35% -47.36% -39.35% Opus Genetics -892.36% -338.88% -191.21%

Does the media refer more to IMTX or IRD?

In the previous week, Opus Genetics had 1 more articles in the media than Immatics. MarketBeat recorded 3 mentions for Opus Genetics and 2 mentions for Immatics. Immatics' average media sentiment score of 0.93 beat Opus Genetics' score of 0.23 indicating that Immatics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Immatics 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Opus Genetics 2 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media prefer CRVS or IRD?

In the previous week, Corvus Pharmaceuticals had 2 more articles in the media than Opus Genetics. MarketBeat recorded 5 mentions for Corvus Pharmaceuticals and 3 mentions for Opus Genetics. Corvus Pharmaceuticals' average media sentiment score of 1.07 beat Opus Genetics' score of 0.23 indicating that Corvus Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Corvus Pharmaceuticals 3 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Opus Genetics 2 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media favor IRD or AVLN?

In the previous week, Opus Genetics and Opus Genetics both had 3 articles in the media. Avalyn Pharma's average media sentiment score of 0.64 beat Opus Genetics' score of 0.23 indicating that Avalyn Pharma is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Opus Genetics 2 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Avalyn Pharma 1 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Is IRD or SDGR more profitable?

Schrodinger has a net margin of -40.61% compared to Opus Genetics' net margin of -892.36%. Schrodinger's return on equity of -30.85% beat Opus Genetics' return on equity. Company Net Margins Return on Equity Return on Assets Opus Genetics -892.36% -338.88% -191.21% Schrodinger -40.61% -30.85% -15.32%

Does the media prefer IRD or SDGR?

In the previous week, Opus Genetics had 2 more articles in the media than Schrodinger. MarketBeat recorded 3 mentions for Opus Genetics and 1 mentions for Schrodinger. Schrodinger's average media sentiment score of 1.88 beat Opus Genetics' score of 0.23 indicating that Schrodinger is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Opus Genetics 2 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Schrodinger 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive

Does the media refer more to CAPR or IRD?

In the previous week, Opus Genetics had 2 more articles in the media than Capricor Therapeutics. MarketBeat recorded 3 mentions for Opus Genetics and 1 mentions for Capricor Therapeutics. Capricor Therapeutics' average media sentiment score of 1.16 beat Opus Genetics' score of 0.23 indicating that Capricor Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Capricor Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Opus Genetics 2 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Opus Genetics (IRD) Competitors

$3.05 -0.22 (-6.73%)

Closing price 04:00 PM Eastern

Extended Trading

$3.18 +0.13 (+4.39%)

As of 07:34 PM Eastern

Compare

IRD vs. IMTX, CRVS, AVLN, SDGR, and CAPR

Should you buy Opus Genetics stock or one of its competitors? MarketBeat compares Opus Genetics with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Opus Genetics include Immatics (IMTX), Corvus Pharmaceuticals (CRVS), Avalyn Pharma (AVLN), Schrodinger (SDGR), and Capricor Therapeutics (CAPR). These companies are all part of the "pharmaceutical products" industry.

How does Opus Genetics compare to Immatics?

Immatics (NASDAQ:IMTX) and Opus Genetics (NASDAQ:IRD) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their profitability, media sentiment, risk, institutional ownership, valuation, dividends, earnings and analyst recommendations.

64.4% of Immatics shares are held by institutional investors. Comparatively, 15.0% of Opus Genetics shares are held by institutional investors. 11.7% of Opus Genetics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Immatics has a beta of 1.32, suggesting that its stock price is 32% more volatile than the broader market. Comparatively, Opus Genetics has a beta of 0.55, suggesting that its stock price is 45% less volatile than the broader market.

Immatics has a net margin of -572.35% compared to Opus Genetics' net margin of -892.36%. Immatics' return on equity of -47.36% beat Opus Genetics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Immatics	-572.35%	-47.36%	-39.35%
Opus Genetics	-892.36%	-338.88%	-191.21%

In the previous week, Opus Genetics had 1 more articles in the media than Immatics. MarketBeat recorded 3 mentions for Opus Genetics and 2 mentions for Immatics. Immatics' average media sentiment score of 0.93 beat Opus Genetics' score of 0.23 indicating that Immatics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Immatics	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Opus Genetics	2 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Immatics currently has a consensus price target of $20.80, suggesting a potential upside of 125.35%. Opus Genetics has a consensus price target of $10.77, suggesting a potential upside of 253.09%. Given Opus Genetics' stronger consensus rating and higher probable upside, analysts plainly believe Opus Genetics is more favorable than Immatics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Immatics	1 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.63
Opus Genetics	2 Sell rating(s)	0 Hold rating(s)	14 Buy rating(s)	1 Strong Buy rating(s)	2.82

Opus Genetics has lower revenue, but higher earnings than Immatics. Immatics is trading at a lower price-to-earnings ratio than Opus Genetics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Immatics	$54.60M	22.66	-$222.26M	-$1.99	N/A
Opus Genetics	$14.20M	17.74	-$49.59M	-$1.33	N/A

Summary

Opus Genetics beats Immatics on 9 of the 17 factors compared between the two stocks.

How does Opus Genetics compare to Corvus Pharmaceuticals?

Corvus Pharmaceuticals (NASDAQ:CRVS) and Opus Genetics (NASDAQ:IRD) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their profitability, earnings, risk, dividends, analyst recommendations, media sentiment, institutional ownership and valuation.

Corvus Pharmaceuticals has a beta of 0.82, suggesting that its share price is 18% less volatile than the broader market. Comparatively, Opus Genetics has a beta of 0.55, suggesting that its share price is 45% less volatile than the broader market.

Corvus Pharmaceuticals presently has a consensus target price of $33.33, indicating a potential upside of 136.41%. Opus Genetics has a consensus target price of $10.77, indicating a potential upside of 253.09%. Given Opus Genetics' stronger consensus rating and higher probable upside, analysts clearly believe Opus Genetics is more favorable than Corvus Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Corvus Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.71
Opus Genetics	2 Sell rating(s)	0 Hold rating(s)	14 Buy rating(s)	1 Strong Buy rating(s)	2.82

46.6% of Corvus Pharmaceuticals shares are held by institutional investors. Comparatively, 15.0% of Opus Genetics shares are held by institutional investors. 19.7% of Corvus Pharmaceuticals shares are held by insiders. Comparatively, 11.7% of Opus Genetics shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Corvus Pharmaceuticals has a net margin of 0.00% compared to Opus Genetics' net margin of -892.36%. Corvus Pharmaceuticals' return on equity of -38.92% beat Opus Genetics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Corvus Pharmaceuticals	N/A	-38.92%	-35.75%
Opus Genetics	-892.36%	-338.88%	-191.21%

In the previous week, Corvus Pharmaceuticals had 2 more articles in the media than Opus Genetics. MarketBeat recorded 5 mentions for Corvus Pharmaceuticals and 3 mentions for Opus Genetics. Corvus Pharmaceuticals' average media sentiment score of 1.07 beat Opus Genetics' score of 0.23 indicating that Corvus Pharmaceuticals is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Corvus Pharmaceuticals	3 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Opus Genetics	2 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Corvus Pharmaceuticals has higher earnings, but lower revenue than Opus Genetics. Corvus Pharmaceuticals is trading at a lower price-to-earnings ratio than Opus Genetics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Corvus Pharmaceuticals	N/A	N/A	-$15.28M	-$0.52	N/A
Opus Genetics	$14.20M	17.74	-$49.59M	-$1.33	N/A

Summary

Corvus Pharmaceuticals beats Opus Genetics on 10 of the 16 factors compared between the two stocks.

How does Opus Genetics compare to Avalyn Pharma?

Opus Genetics (NASDAQ:IRD) and Avalyn Pharma (NASDAQ:AVLN) are both small-cap pharmaceutical products companies, but which is the better investment? We will contrast the two companies based on the strength of their media sentiment, profitability, valuation, institutional ownership, analyst recommendations, earnings, risk and dividends.

Avalyn Pharma has a net margin of 0.00% compared to Opus Genetics' net margin of -892.36%. Avalyn Pharma's return on equity of 0.00% beat Opus Genetics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Opus Genetics	-892.36%	-338.88%	-191.21%
Avalyn Pharma	N/A	N/A	N/A

15.0% of Opus Genetics shares are owned by institutional investors. 11.7% of Opus Genetics shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Avalyn Pharma has lower revenue, but higher earnings than Opus Genetics. Opus Genetics is trading at a lower price-to-earnings ratio than Avalyn Pharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Opus Genetics	$14.20M	17.74	-$49.59M	-$1.33	N/A
Avalyn Pharma	N/A	N/A	N/A	-$21.83	N/A

In the previous week, Opus Genetics and Opus Genetics both had 3 articles in the media. Avalyn Pharma's average media sentiment score of 0.64 beat Opus Genetics' score of 0.23 indicating that Avalyn Pharma is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Opus Genetics	2 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Avalyn Pharma	1 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Opus Genetics currently has a consensus price target of $10.77, suggesting a potential upside of 253.09%. Avalyn Pharma has a consensus price target of $59.00, suggesting a potential upside of 106.08%. Given Opus Genetics' higher possible upside, research analysts clearly believe Opus Genetics is more favorable than Avalyn Pharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Opus Genetics	2 Sell rating(s)	0 Hold rating(s)	14 Buy rating(s)	1 Strong Buy rating(s)	2.82
Avalyn Pharma	0 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	2 Strong Buy rating(s)	3.20

Summary

Avalyn Pharma beats Opus Genetics on 7 of the 13 factors compared between the two stocks.

How does Opus Genetics compare to Schrodinger?

Opus Genetics (NASDAQ:IRD) and Schrodinger (NASDAQ:SDGR) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their dividends, media sentiment, risk, analyst recommendations, institutional ownership, profitability, valuation and earnings.

In the previous week, Opus Genetics had 2 more articles in the media than Schrodinger. MarketBeat recorded 3 mentions for Opus Genetics and 1 mentions for Schrodinger. Schrodinger's average media sentiment score of 1.88 beat Opus Genetics' score of 0.23 indicating that Schrodinger is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Opus Genetics	2 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Schrodinger	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive

Opus Genetics presently has a consensus price target of $10.77, indicating a potential upside of 253.09%. Schrodinger has a consensus price target of $20.25, indicating a potential upside of 35.00%. Given Opus Genetics' stronger consensus rating and higher probable upside, research analysts plainly believe Opus Genetics is more favorable than Schrodinger.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Opus Genetics	2 Sell rating(s)	0 Hold rating(s)	14 Buy rating(s)	1 Strong Buy rating(s)	2.82
Schrodinger	1 Sell rating(s)	4 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.33

Schrodinger has a net margin of -40.61% compared to Opus Genetics' net margin of -892.36%. Schrodinger's return on equity of -30.85% beat Opus Genetics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Opus Genetics	-892.36%	-338.88%	-191.21%
Schrodinger	-40.61%	-30.85%	-15.32%

Opus Genetics has a beta of 0.55, indicating that its share price is 45% less volatile than the broader market. Comparatively, Schrodinger has a beta of 1.62, indicating that its share price is 62% more volatile than the broader market.

Opus Genetics has higher earnings, but lower revenue than Schrodinger. Schrodinger is trading at a lower price-to-earnings ratio than Opus Genetics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Opus Genetics	$14.20M	17.74	-$49.59M	-$1.33	N/A
Schrodinger	$255.87M	4.33	-$103.26M	-$1.41	N/A

15.0% of Opus Genetics shares are held by institutional investors. Comparatively, 79.1% of Schrodinger shares are held by institutional investors. 11.7% of Opus Genetics shares are held by insiders. Comparatively, 10.1% of Schrodinger shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Summary

Opus Genetics beats Schrodinger on 10 of the 17 factors compared between the two stocks.

How does Opus Genetics compare to Capricor Therapeutics?

Capricor Therapeutics (NASDAQ:CAPR) and Opus Genetics (NASDAQ:IRD) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their profitability, media sentiment, dividends, institutional ownership, risk, valuation, analyst recommendations and earnings.

21.7% of Capricor Therapeutics shares are owned by institutional investors. Comparatively, 15.0% of Opus Genetics shares are owned by institutional investors. 9.2% of Capricor Therapeutics shares are owned by insiders. Comparatively, 11.7% of Opus Genetics shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

In the previous week, Opus Genetics had 2 more articles in the media than Capricor Therapeutics. MarketBeat recorded 3 mentions for Opus Genetics and 1 mentions for Capricor Therapeutics. Capricor Therapeutics' average media sentiment score of 1.16 beat Opus Genetics' score of 0.23 indicating that Capricor Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Capricor Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Opus Genetics	2 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Opus Genetics has lower revenue, but higher earnings than Capricor Therapeutics. Capricor Therapeutics is trading at a lower price-to-earnings ratio than Opus Genetics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Capricor Therapeutics	$22.27M	50.71	-$105.04M	-$2.32	N/A
Opus Genetics	$14.20M	17.74	-$49.59M	-$1.33	N/A

Capricor Therapeutics has a net margin of 0.00% compared to Opus Genetics' net margin of -892.36%. Capricor Therapeutics' return on equity of -59.27% beat Opus Genetics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Capricor Therapeutics	N/A	-59.27%	-48.65%
Opus Genetics	-892.36%	-338.88%	-191.21%

Capricor Therapeutics currently has a consensus price target of $53.67, indicating a potential upside of 175.21%. Opus Genetics has a consensus price target of $10.77, indicating a potential upside of 253.09%. Given Opus Genetics' higher probable upside, analysts clearly believe Opus Genetics is more favorable than Capricor Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Capricor Therapeutics	1 Sell rating(s)	0 Hold rating(s)	8 Buy rating(s)	1 Strong Buy rating(s)	2.90
Opus Genetics	2 Sell rating(s)	0 Hold rating(s)	14 Buy rating(s)	1 Strong Buy rating(s)	2.82

Capricor Therapeutics has a beta of 0.42, meaning that its share price is 58% less volatile than the broader market. Comparatively, Opus Genetics has a beta of 0.55, meaning that its share price is 45% less volatile than the broader market.

Summary

Capricor Therapeutics and Opus Genetics tied by winning 8 of the 16 factors compared between the two stocks.

Get Opus Genetics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding IRD and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

IRD vs. The Competition

Export

Metric	Opus Genetics	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$269.99M	$3.69B	$6.90B	$12.28B
Dividend Yield	N/A	2.16%	2.67%	9.36%
P/E Ratio	-2.29	10.89	22.26	21.51
Price / Sales	17.74	300.39	517.96	91.07
Price / Cash	N/A	60.31	26.68	47.25
Price / Book	13.86	7.92	10.66	6.14
Net Income	-$49.59M	$23.81M	$3.60B	$331.74M
7 Day Performance	-19.95%	-1.27%	-1.51%	-1.72%
1 Month Performance	-25.06%	2.56%	1.11%	-1.44%
1 Year Performance	169.91%	42.49%	23.77%	16.97%

Opus Genetics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
IRD Opus Genetics	2.8543 of 5 stars	$3.05 -6.7%	$10.77 +253.1%	+189.4%	$269.99M	$14.20M	N/A	14
IMTX Immatics	2.4634 of 5 stars	$9.35 +1.3%	$20.80 +122.5%	+59.8%	$1.24B	$54.60M	N/A	260	Gap Up
CRVS Corvus Pharmaceuticals	2.9665 of 5 stars	$14.97 +1.8%	$33.33 +122.7%	+249.8%	$1.24B	N/A	N/A	30	Positive News
AVLN Avalyn Pharma	4.1166 of 5 stars	$28.28 +1.6%	$59.00 +108.6%	N/A	$1.23B	N/A	N/A	51
SDGR Schrodinger	2.4779 of 5 stars	$16.13 -1.7%	$20.25 +25.5%	-28.6%	$1.21B	$255.87M	N/A	790

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:IRD) was last updated on 7/20/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Opus Genetics (IRD) Competitors

IRD vs. IMTX, CRVS, AVLN, SDGR, and CAPR

How does Opus Genetics compare to Immatics?

Summary

How does Opus Genetics compare to Corvus Pharmaceuticals?

Summary

How does Opus Genetics compare to Avalyn Pharma?

Summary

How does Opus Genetics compare to Schrodinger?

Summary

How does Opus Genetics compare to Capricor Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

IRD vs. The Competition

Opus Genetics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Opus Genetics (IRD) Competitors

IRD vs. IMTX, CRVS, AVLN, SDGR, and CAPR

How does Opus Genetics compare to Immatics?

Do insiders and institutionals have more ownership in IMTX or IRD?

Which has more risk & volatility, IMTX or IRD?

Is IMTX or IRD more profitable?

Does the media refer more to IMTX or IRD?

Do analysts rate IMTX or IRD?

Which has higher earnings & valuation, IMTX or IRD?

Summary

How does Opus Genetics compare to Corvus Pharmaceuticals?

Which has more risk & volatility, CRVS or IRD?

Do analysts prefer CRVS or IRD?

Do institutionals and insiders believe in CRVS or IRD?

Is CRVS or IRD more profitable?

Does the media prefer CRVS or IRD?

Which has better earnings and valuation, CRVS or IRD?

Summary

How does Opus Genetics compare to Avalyn Pharma?

Is IRD or AVLN more profitable?

Do insiders & institutionals believe in IRD or AVLN?

Which has stronger valuation and earnings, IRD or AVLN?

Does the media favor IRD or AVLN?

Do analysts rate IRD or AVLN?

Summary

How does Opus Genetics compare to Schrodinger?

Does the media prefer IRD or SDGR?

Do analysts prefer IRD or SDGR?

Is IRD or SDGR more profitable?

Which has more volatility & risk, IRD or SDGR?

Which has stronger earnings & valuation, IRD or SDGR?

Do institutionals and insiders have more ownership in IRD or SDGR?

Summary

How does Opus Genetics compare to Capricor Therapeutics?

Do insiders & institutionals hold more shares of CAPR or IRD?

Does the media refer more to CAPR or IRD?

Which has stronger valuation and earnings, CAPR or IRD?

Is CAPR or IRD more profitable?

Do analysts prefer CAPR or IRD?

Which has more volatility and risk, CAPR or IRD?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

IRD vs. The Competition

Opus Genetics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools